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Introduction
Acute leukaemias represent neoplasm of the
haematopoietic cell precursors manifested as clonal
expansion of myeloid and lymphoid haematopoiesis. Acute
Myelogenous Leukaemia (AML) represents group of
haematological malignancies that arise within bone marrow
precursors of myeloid, monocyte, erythroid and
megakaryocytic cell lineages.1
Contrary to Acute Lymphoblastic Leukaemia of the
late 1970's only modest improvement in the long-term
survival of children with AML has been observed. However,
over the last few years' treatment modification,
intensification, introduction of new chemotherapeutic agents,
targeted therapy and concomitant haematopoietic stem cell
transplantation in high risk patients has improved overall
survival in children with AML up to 50-60 %.2-4
Acute Myeloid Leukaemia represents 15%-20% of all
leukaemias in children less than 14 years of age with Acute
Leukaemia constituting 30% of all childhood malignancies.
Literature has shown that estimated incidence of childhood
AML is 5-7 per million people per year and the frequency
remains static throughout childhood with slight increase in
adolescence.2 There is no sex predilection but there is some
difference in certain ethnic and racial groups.5 A few
predisposing factors such as environmental, genetic and
acquired also increase the risk of AML.2 The diagnosis of
AML is established with a combination of morphologic,
immunophenotypic and cytogenetic features.
To date very little information is available from our
country on the frequency, subtype, presentation and outcome
of childhood acute myeloid leukaemia. The majority of
published data focuses on morphology and refers to both
adults and children.6-8Our study is a single centre based study
and may not reflect the overall presentation and outcome of
Paediatric AML in our country.
Patients and Methods
A retrospective descriptive study was conducted at the
Aga Khan University Hospital, Karachi, Pakistan on children
(less than 15 years) from January 2000 to May 2007. Forty
cases were diagnosed as AML during this period and 37
charts were available for analysis. 
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Objective: To document the demographics and outcome of children with Acute Myeloid Leukemia (AML) treated
at a tertiary care facility of Pakistan.
Methods: A retrospective study was conducted at Aga Khan University on children (less than 15 years)
diagnosed to have AML between January 2000 to May 2007.Total 40 cases were diagnosed out of which 37
charts were available for review.
Results: The average age of presentation was 8.5±4.5 years and 75% were males. The most common
presenting feature was fever in 83% followed by bleeding in 41% and pallor in 39%. Initial WBC of > 100,000
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treatment out of which 12 patients are alive and in remission. Majority were followed up around 2 years and 6
months. Out of the 11 patients who died three had resistant disease, four relapsed and rest died due to sepsis
mostly during induction.
Conclusions: The most common sub type in our study is AML M4 although AML M2 is reported as predominant
subtype. About a third of the patients could not start or complete therapy due to financial constraints. The overall
survival for our patients who completed therapy was 52%.
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Results
From January 2000 to May 2007, 40 children <15
years were diagnosed as AML. Of these 37 charts were
available for review. Out of these 37 patients only 23 (62%)
had undergone complete treatment. Remaining children's
parents refused treatment or were referred elsewhere due to
financial constraints or other social problems. 
There were 9 (25%) females and 28 (75%) males.
Average age at diagnosis was 8.5±4.5 years (6mo-15 years)
and median of 10 years. Varied clinical presentations were
found. Fever was the most common presenting feature in 31
(83%) followed by, bleeding/bruising in 15 (41%) and pallor
in 14 (38%). One patient had associated Downs syndrome
and two patients presented with bilateral proptosis.
Hyperleukocytosis is one of the important prognostic
indicators. In our study 17 (46 %) patients had W.B.C between
0-20,000 x109/L, 13 (35%) had 20,000- 100,000x109/L and 7
(19%) patients had WBC >100,000x109/L at presentation. 
High LDH of >1000 IU/L was found in 50% patients.
The most common FAB (French-American-British) subtype
was M4 39% followed by M2 16 % M3 and M6 each 14 %
and M5 3% (Table-1).
CNS (central nervous system) disease was present in
5 (13%) patients. M4 was the predominant subtype in CNS
positive children. One of these patients also had
hyperleukocytosis.
The patients were initially treated on POG (Pediatric
Oncology Group) 9421-DAT (daunomycin, cytosine
arabinoside and Thioguanine) based protocols, from 2000-2002
and then changed to Medical Research Council (MRC) AML 10
protocol. The children with APML-M3 (Acute Promyelocytic
Leukaemia) were treated with chemotherapy and All Trans
retinoic acid (ATRA) based on COG (Children Oncology
Group) protocol with one year of maintenance therapy. The
details of chemotherapy are further explained in Table-2.
Three patients out of twenty three had resistant
disease and their FAB subtypes were M6 and M4. Resistant
disease was defined as no remission (marrow blasts > 20%)
even after two courses of induction therapy. These patients
were then put on palliative/supportive care only. Relapses
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Table-1: Patient’s characteristics.
Sex Alive Expired
Male 07 08
Female 05 03
Fab Classification
M2 02 02
APML 04 -
M4 04 05
M5 01 -
M6 01 02
Treatment Options
MRC 04 04
DAT 04 07
COG based ATRA 04
CNS Disease ( Total 5)*
*2 left against medical advise 02 01
FAB classification: French American British. APML: Acute Promyclocytic
Leukaemia. MRC: Medical Research Council. DAT: Daunomycin, Cystosine
Avabinoside and Thiogvanine. COG: Children Oncology Group. CNS: Central
Nervous System.
Table-2: Treatment Scheme applied in 23 patients with AML
diagnosed at Aga Khan University Hospital (Jan 2000-May 2007).
DAT Based Therapy
Phase of Drug Dose Administration
Chemotherapy & Duration
Induction Daunomycin 45mg/m2 IV  Day 1-3
(Course 1&2) Ara-C 100mg/m2 IV  Day 1-7
6TG 100mg/m2 PO day1-7
*Ara-C 40mg/m2 IT  Day 1 only
Consolidation VP 16 100mg/m2 IV   Day1-5
(Course 1& 3) Mitoxantrone 10mg/m2 IV   Day1-4
*Ara-C 40mg/m2 IT   Day 1 only
Consolidation
(Course 2) Ara-C 1 gm/m2 IV Day 1-5
Q12Hrly
MRC Based Therapy
Induction Ara-C 100mg/m2 IV  Day 1-8
Q12Hrly
(Course 1& 2) Daunorubicicn 50 mg/m2 IV Day1, 3 & 5
ADE VP 16 100mg/m2 IV   Day1-5
Triple IT Day 1 only
(HC, Ara-C, MTX)
Post Induction Idarubicin 10mg/m2 IV Day 1-2
(Course 3) Cytarabine 200mg/m2 IV Day 1-5
VP 16 100mg/m2 IV Day1-5
Consolidation
(Course 4) Ara-C 3gm/m2 IV Day1,2,8 and 9
CLASP Asparginase 6000/mgm2 IV  Day 2& 9
(Course 5) Mitoxantrone 10mg/m2 IV Day1-5
Mida A Ara-C 1gm/m2 IV Day 1-3
Q12hrly
ATRA based APML
Therapy
Induction Daunorubicin 50mg/m2 IV Day3-6
Ara-C 200mg/m2 IV Day 1-7
ATRA 45mg/m2 PO till complete
response
Ara-C IT day 1 only
Consolidation
(Course 1& 2) ATRA 45mg/m2 PO Day 1-7 
Daunorubicin 50 mg/m2 IV Day 1-3
Maintenance ATRA 45mg/m2 PO Day1-7 alternate
week for 1 year
6MP 60 mg/m2 PO daily 1 year
Methotrexate 20 mg/m2 PO once a week
for 1 year
* Note CSF positive patients should receive total 6 doses of Triple IT in a period of
3 weeks following diagnosis of AML.
HC hydrocortisone, Ara-C cytarabine, MTX methotrexate, VP-16 etoposide, ATRA
all trans retinoic acid, IV intravenous, PO oral, IT intrathecal.
were seen in 4 and in one patient with Down's syndrome.
Three were isolated BM (bone marrow) relapse and 1 had
BM and CSF (cerebro-spinal fluid) combined. Three opted
for further therapy; two went into second remission and
received Bone Marrow Transplant successfully, while the
others succumbed to their disease. Four children died due to
sepsis, 2 during induction therapy and 1 died during re-
induction of relapsed disease. One patient had
hyperleukcocytosis and died due to sepsis and acute renal
failure prior to any therapy.
Thus at the time of analysis, 52% (12/23) of those
patients who completed treatment, are alive and in remission.
The average length of follow up for these patients is 2 years
and 6 months (range 12 months to 72 months).
Discussion
Over the last couple of years the prognosis for
children with AML has shown improvement. Some of the
trials have quoted a complete remission rate of more than
90% with an overall survival rate of about 50-60% as half of
them will experience relapse.1 Though the main reason of
treatment failure in AML is the recurrent/resistant disease,
death due to treatment related toxicities and infections also
contribute to the overall morbidity and mortality.9 In the
Medical Research Council (MRC) AML10 trial, the overall
survival rate was found to be 57%, showing marked
improvement as compared to the previous trials but treatment
related mortality was nearly 14%.10
The clinical presentation of AML maybe diverse and
nonspecific, but is usually directly related to the leukaemic
infiltration of the bone marrow, with resultant cell lines
depression. Patients typically present with signs and
symptoms of fatigue and pallor, bleeding, fever and
infections due to myelosuppression of red cells, platelets, and
white cells, respectively. Other features of presentation may
include bone pains, hepatomegaly and splenomegaly,
granulocytic sarcomas in orbit or periorbital area or at times
with involvement of spinal cord presenting as spinal cord
compression.2
In our study we have evaluated the different clinical
presentations and laboratory data of children with AML.
The average age of diagnosis of AML was 8.5 ± 4.5years
with marked male predominance, 75% compared to 25%
females. Although this has also been observed in other
studies6,7,11 our data may be biased due to gender
preference in our society. The outcome observed was
better in females. Fever is considered as the most common
presentation of AML.1,2 In our patients it was found in
83% followed by bleeding/bruising in 41% and pallor in
39% of patients. Factors such as WBC, morphologic
classification (FAB classification), and biological
characteristics such as immunophenotype and cytogenetic
are considered as prognostic markers. White Blood Cell
counts have also important relationship with the prognosis
in AML. Various studies have shown a WBC count of
<20,000 cells/ml3 is associated with a better prognosis,
and a WBC of >100,000 cells/ml3 is associated with
unfavourable outcome.12,13 In our study 19% of patients
had white cell count > 100000 cells/ml3. 
Metabolic derangements are important features that
can be present in these patients at the time of diagnosis or
arise secondary to therapy. This is dependent on the tumour
cells burden and leukaemic cell turnover rate. Children can
present with mild to severe hyperuricaemia, hyperkalaemia,
hyperphosphataemia, and hypocalcaemia.2 One of our
patients who presented with metabolic derangements died in
induction phase of chemotherapy due to tumour lysis
syndrome and acute renal failure. Patients with M3 AML
(APL) and M5 AML (monocytic) are more likely to show
signs of DIC with associated laboratory abnormalities such as
prolonged prothrombin time (PT), partial thromboplastin
time (PTT), and decreased fibrinogen.2 In our study four
patients had APML (3 females and 1 male) and all are alive
till the time of evaluation.
CNS disease is more common in M4 and M5 AML as
well as those with high white cell count.2 In our study five
patients had CNS disease and all were with M4 subtype. 
Till a few years back AML was classified on the basis
of morphologic appearance using the FAB classification.
Because of the limitations of this classification and lack of
consistency or association with underlying biology, the World
Health Organization (WHO) recently developed a system for
comprehensive AML classification based on cytogenetics,
disease biology, and clinical history.2,14 Cytogenetics looking
at specific molecular translocations found in AML were
available at our institute only after 2004, thus for this study,
we only used morphological FAB for further classification. In
our study the most common FAB subtype found was M4 38%
followed by M2 16%, M3 and M6 each 14 % then M5 3%
although internationally AML M2 and M4 has been reported
as predominant subtype.2,15,16 This is followed by M1 20%,
M5 15% (note age < 2 years M5 is nearly 50%), M3 5%-
10%, M6 < 5%, M7 3% and M0 <3%. Even the studies
carried out in adult population are predictive of M2 subtype
as the most common. This difference has also been reported
in another study from our institution and other studies carried
out elsewhere in our country.6-8
From 2000-2002 the children were treated on the
POG 9421-DAT based therapy and then the therapy was
changed to MRC- AML 10 based protocol. AML M3 was
treated with ATRA plus chemotherapy based on COG
protocol with one year maintenance. Improved outcome has
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been reported with the use of MRC AML 10 protocol which
was also observed in our study.17 As cytogenetics were not
available for majority of patients thus risk stratification could
be done and all were treated with the same regimen except for
those with APML who were considered good risk and treated
using ATRA based protocol.
Recurrence of childhood myeloid leukaemia is
associated with poor outcome.18 In our study 23 patients were
able to complete their treatment. Those who were not able to
complete treatment either had financial constraints or refused
any treatment. The outcome of these patients is unknown as
none came for follow-up. The patients with resistant disease
were only offered supportive care.
Out of 23, 12 (52%) patients were in remission and in
our follow up at the time of analysis. Three out of the four
patients with relapsed disease were treated with second line
therapy using FLAG. Two patients who achieved second
induction remission underwent bone marrow transplantation
successfully. Although Down's syndrome patients have a
better prognosis but unfortunately our patient relapsed and
the family decided for no further treatment. The average
length of follow up period of our patients after completion of
therapy was 2 years and 6 months with the longest survival
being 6 years.
Resistant disease, relapses and infections are the most
common attributable factors for deaths in AML which was
also seen in our patients. 
Over the years outcome of AML patients has
improved because of diagnostic and prognostic factors,
subgroup-risk directed treatment, targeted therapy and stem
cell transplantation. With the progress in the understanding of
biology of AML and development of new molecular targeted
therapy in combination with chemotherapy and better
supportive care, survival of children with acute myeloid
leukaemia will further improve.
Our study is a single institution based study and may
not be able to depict the overall status of children with AML
in our country. Further data from other centres or multicenter
studies are needed to demonstrate the overall incidence and
survival of children with AML in Pakistan.
Although this study may not be comparable to the
survival data from the more developed countries, it is enough
to encourage physicians to at least try and treat these patients
and refer them as early as possible. With improved resources,
availability of targeted therapies and haematopoietic stem cell
transplantation, development of better diagnostic facilities
especially cytogenetics and better supportive care, we can
achieve a better overall survival rate.
Conclusion
Majority of children were males however survival
was better in females. About a third of the patients in our
study could not start or complete therapy due to financial
constraints. Even with these limitations overall survival for
our patients who completed therapy was 50%.
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